OXiGENE, a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, says that its lead product candidate, Zybrestat (combretastatin-A4 phosphate), has achieved the pre-specified primary efficacy endpoint for Stage 1 of an ongoing Phase II ovarian cancer clinical trial. The study utilized an open-label, Simon two-stage design to evaluate the combination of Zybrestat, carboplatin and paclitaxel in patients with advanced, platinum-resistant ovarian cancer, a refractory form of the disease for which therapeutic options are limited. Having met the Stage 1 primary efficacy endpoint, the clinical trial will proceed to its second stage, in which an additional 25 patients will be enrolled.
"These results add to the growing body of data indicating that Zybrestat has clinical activity against a wide variety of solid tumors, particularly when administered in combination with conventional chemotherapeutic agents," commented Patricia Walicke, chief medical officer of OXiGENE.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze